Patented Medicine Prices Review Board

Patented Medicine Prices Review Board

May 24, 2006 16:00 ET

The Board Will Hold Consultations on its Excessive Price Guidelines

OTTAWA, ONTARIO--(CCNMatthews - May 24, 2006) - The Patented Medicine Prices Review Board has released a Discussion Guide for Consultations on the Board's Excessive Price Guidelines.

The document is posted on the PMPRB Web site and is available to all interested parties who wish to comment. Dr. Brien Benoit, Vice-Chairperson of the Board, stated that "the Board wishes to engage its stakeholders in a dialogue to better understand the issues with the current Guidelines and to explore potential options for change."

Consultation events are planned for five Canadian cities in November 2006. The purpose is to build on comments that will have been received on the Discussion Guide.

Interested parties have until August 25 to comment on the Discussion Guide. All comments are to be forwarded by mail, fax, or e-mail, to the Secretary of the Board.

The PMPRB is the federal agency responsible for pharmaceutical pricing and analysis in Canada. It is an independent quasi-judicial tribunal with a dual responsibility - a regulatory mandate to ensure that the prices charged by manufacturers of patented medicines are not excessive; and a reporting mandate to analyze and report on pharmaceutical price and cost trends and on patentees' R&D expenditures.

Contact Information